{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:01:22Z","timestamp":1794668482696,"version":"4.9.1"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"crossref","award":["NRF-2019M2D2A1A01058210, NRF-2020R1C1C1009000, 2021M2E8A1039564, RS-2025-005142101"],"award-info":[{"award-number":["NRF-2019M2D2A1A01058210, NRF-2020R1C1C1009000, 2021M2E8A1039564, RS-2025-005142101"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although therapeutic options for inflammatory bowel disease (IBD) have advanced, many patients still experience suboptimal clinical response, systemic side effects, or difficulty maintaining long-term treatment adherence. Hydrogen sulfide (H\u2082S), an endogenous gasotransmitter with potent anti-inflammatory and mucosal-protective properties, has shown promise as a therapeutic agent for IBD. However, clinical application has been constrained by its instability in low pH and the need for parenteral administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Here, we report the first orally administered, pH-responsive liposomal formulation of the H\u2082S donor GYY4137, specifically designed for colon-targeted delivery. This system, termed oral hydrogen sulfide donor-loaded liposome (Oral H\u2082S lipo), employs a pH-sensitive Eudragit S100 coating that forms protective aggregates under acidic gastric conditions (pH 2) to shield the liposomes and suppress premature H\u2082S release. In this environment, Oral H\u2082S lipo limited cumulative release of H\n                      <jats:sub>2<\/jats:sub>\n                      S to 12.13% over 8\u00a0days, representing a\u2009~\u2009fivefold reduction compared to free GYY4137 (60% release). Upon exposure to colonic pH (\u2265\u20097), the coating dissolved, restoring the native liposomal state as evidenced by a reduction in polydispersity index (PDI) from 0.777 to 0.076, and enabling sustained H\n                      <jats:sub>2<\/jats:sub>\n                      S release. The formulation also exhibited high drug loading efficiency (74.65%), stable physicochemical properties across gastrointestinal pH conditions for at least 14\u00a0days and excellent in vitro biocompatibility over a wide concentration range (0\u2013120\u00a0\u03bcM). In vivo fluorescence imaging in a dextran sodium sulfate (DSS)-induced colitis model demonstrated that DiR-labeled Oral H\u2082S lipo achieved\u2009~\u20092.4-fold higher colonic accumulation than free DiR (p\u2009&lt;\u20090.01) and\u2009~\u20091.7-fold higher than DiR-H\u2082S lipo (p\u2009&lt;\u20090.05), validating the functionality of the pH-responsive coating for site-specific drug release. Therapeutic studies further showed improved colon length, reduced histological inflammation, and preservation of mucosal structure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings demonstrate that Oral H\u2082S lipo enables effective, site-specific delivery of H\u2082S to inflamed colonic tissue, offering a clinically relevant platform to overcome limitations of conventional H\u2082S donor therapies in IBD management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12951-025-03753-9","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:24:14Z","timestamp":1762874654000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["pH-responsive Oral liposomal delivery of hydrogen sulfide donor GYY4137 enables colon-targeted therapy for inflammatory bowel disease"],"prefix":"10.1186","volume":"23","author":[{"given":"Chiwoo","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee-Eun","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunjoon","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haena","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo-young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Kyoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Jun","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"3753_CR1","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1056\/NEJMra0804647","volume":"361","author":"C Abraham","year":"2009","unstructured":"Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066\u201378.","journal-title":"N Engl J Med"},{"key":"3753_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0205-x","volume":"6","author":"T Kobayashi","year":"2020","unstructured":"Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6:74.","journal-title":"Nat Rev Dis Primers"},{"key":"3753_CR3","doi-asserted-by":"publisher","first-page":"675","DOI":"10.14309\/ajg.0000000000003143","volume":"120","author":"P Danpanichkul","year":"2025","unstructured":"Danpanichkul P, Duangsonk K, Ho AHY, Laoveeravat P, Vuthithammee C, Dejvajara D, et al. Disproportionately increasing incidence of inflammatory bowel disease in female patients and the elderly: an update analysis from the global burden of disease study 2021. Am J Gastroenterol. 2025;120:675\u201380.","journal-title":"Am J Gastroenterol"},{"key":"3753_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00384-024-04711-x","volume":"39","author":"D Lin","year":"2024","unstructured":"Lin D, Jin Y, Shao X, Xu Y, Ma G, Jiang Y, et al. Global, regional, and national burden of inflammatory bowel disease, 1990\u20132021: insights from the global burden of disease 2021. Int J Colorectal Dis. 2024;39:139.","journal-title":"Int J Colorectal Dis"},{"key":"3753_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-065186","volume":"13","author":"R Wang","year":"2023","unstructured":"Wang R, Li Z, Liu S, Zhang D. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ Open. 2023;13:e065186.","journal-title":"BMJ Open"},{"key":"3753_CR6","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","volume":"12","author":"GG Kaplan","year":"2015","unstructured":"Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720\u20137.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3753_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120461","volume":"600","author":"W Liu","year":"2021","unstructured":"Liu W, Dong Z, Liu K, Lu Y, Wu W, Qi J, et al. Targeting strategies of oral nano-delivery systems for treating inflammatory bowel disease. Int J Pharm. 2021;600:120461.","journal-title":"Int J Pharm"},{"key":"3753_CR8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1136\/gutjnl-2012-303207","volume":"63","author":"ME Johansson","year":"2014","unstructured":"Johansson ME, Gustafsson JK, Holmen-Larsson J, Jabbar KS, Xia L, Xu H, et al. Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut. 2014;63:281\u201391.","journal-title":"Gut"},{"key":"3753_CR9","first-page":"72","volume":"113","author":"J Wehkamp","year":"2016","unstructured":"Wehkamp J, Gotz M, Herrlinger K, Steurer W, Stange EF. Inflammatory bowel disease. Dtsch Arztebl Int. 2016;113:72\u201382.","journal-title":"Dtsch Arztebl Int"},{"key":"3753_CR10","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.mayocp.2014.07.002","volume":"89","author":"JD Feuerstein","year":"2014","unstructured":"Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89:1553\u201363.","journal-title":"Mayo Clin Proc"},{"key":"3753_CR11","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.autrev.2014.01.028","volume":"13","author":"K Conrad","year":"2014","unstructured":"Conrad K, Roggenbuck D, Laass MW. Diagnosis and classification of ulcerative colitis. Autoimmun Rev. 2014;13:463\u20136.","journal-title":"Autoimmun Rev"},{"key":"3753_CR12","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nrgastro.2016.116","volume":"13","author":"P Hindryckx","year":"2016","unstructured":"Hindryckx P, Jairath V, D\u2019Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13:654\u201364.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3753_CR13","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1056\/NEJMra2002697","volume":"383","author":"JT Chang","year":"2020","unstructured":"Chang JT. Pathophysiology of inflammatory bowel diseases. N Engl J Med. 2020;383:2652\u201364.","journal-title":"N Engl J Med"},{"key":"3753_CR14","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","volume":"369","author":"DC Baumgart","year":"2007","unstructured":"Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641\u201357.","journal-title":"Lancet"},{"key":"3753_CR15","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","volume":"158","author":"JD Feuerstein","year":"2020","unstructured":"Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158:1450\u201361.","journal-title":"Gastroenterology"},{"key":"3753_CR16","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1734-1140(11)70575-8","volume":"63","author":"AB Pithadia","year":"2011","unstructured":"Pithadia AB, Jain S. Treatment of inflammatory bowel disease (IBD). Pharmacol Rep. 2011;63:629\u201342.","journal-title":"Pharmacol Rep"},{"key":"3753_CR17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1080\/19490976.2017.1290757","volume":"8","author":"AR Weingarden","year":"2017","unstructured":"Weingarden AR, Vaughn BP. Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease. Gut Microbes. 2017;8:238\u201352.","journal-title":"Gut Microbes"},{"key":"3753_CR18","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/ecco-jcc\/jjv129","volume":"9","author":"SF Jeuring","year":"2015","unstructured":"Jeuring SF, Bours PH, Zeegers MP, Ambergen TW, van den Heuvel TR, Romberg-Camps MJ, et al. Disease outcome of ulcerative colitis in an era of changing treatment strategies: results from the dutch population-based IBDSL cohort. J Crohns Colitis. 2015;9:837\u201345.","journal-title":"J Crohns Colitis"},{"key":"3753_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.268re2","volume":"2","author":"AK Mustafa","year":"2009","unstructured":"Mustafa AK, Gadalla MM, Snyder SH. Signaling by gasotransmitters. Sci Signal. 2009;2:re2.","journal-title":"Sci Signal"},{"key":"3753_CR20","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nrd2425","volume":"6","author":"C Szabo","year":"2007","unstructured":"Szabo C. Hydrogen sulphide and its therapeutic potential. Nat Rev Drug Discov. 2007;6:917\u201335.","journal-title":"Nat Rev Drug Discov"},{"key":"3753_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1089\/ars.2011.4451","volume":"17","author":"C Szabo","year":"2012","unstructured":"Szabo C. Roles of hydrogen sulfide in the pathogenesis of diabetes mellitus and its complications. Antioxid Redox Signal. 2012;17:68\u201380.","journal-title":"Antioxid Redox Signal"},{"key":"3753_CR22","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1139\/y03-077","volume":"81","author":"W Zhao","year":"2003","unstructured":"Zhao W, Ndisang JF, Wang R. Modulation of endogenous production of H2S in rat tissues. Can J Physiol Pharmacol. 2003;81:848\u201353.","journal-title":"Can J Physiol Pharmacol"},{"key":"3753_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1161\/ATVBAHA.108.179333","volume":"29","author":"Y Wang","year":"2009","unstructured":"Wang Y, Zhao X, Jin H, Wei H, Li W, Bu D, et al. Role of hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol. 2009;29:173\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3753_CR24","doi-asserted-by":"publisher","first-page":"G467","DOI":"10.1152\/ajpgi.00169.2013","volume":"305","author":"MV Chan","year":"2013","unstructured":"Chan MV, Wallace JL. Hydrogen sulfide-based therapeutics and gastrointestinal diseases: translating physiology to treatments. Am J Physiol Gastrointest Liver Physiol. 2013;305:G467-473.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"3753_CR25","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1097\/MIB.0000000000000345","volume":"21","author":"JP Motta","year":"2015","unstructured":"Motta JP, Flannigan KL, Agbor TA, Beatty JK, Blackler RW, Workentine ML, et al. Hydrogen sulfide protects from colitis and restores intestinal microbiota biofilm and mucus production. Inflamm Bowel Dis. 2015;21:1006\u201317.","journal-title":"Inflamm Bowel Dis"},{"key":"3753_CR26","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1053\/j.gastro.2009.04.012","volume":"137","author":"JL Wallace","year":"2009","unstructured":"Wallace JL, Vong L, McKnight W, Dicay M, Martin GR. Endogenous and exogenous hydrogen sulfide promotes resolution of colitis in rats. Gastroenterology. 2009;137:569\u201378.","journal-title":"Gastroenterology"},{"key":"3753_CR27","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1096\/fj.07-8669com","volume":"21","author":"JL Wallace","year":"2007","unstructured":"Wallace JL, Dicay M, McKnight W, Martin GR. Hydrogen sulfide enhances ulcer healing in rats. FASEB J. 2007;21:4070\u20136.","journal-title":"FASEB J"},{"key":"3753_CR28","doi-asserted-by":"publisher","first-page":"681","DOI":"10.21037\/atm-22-2126","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu Y, Liao R, Qiang Z, Yang W, Cao J. Exogenous H2S promotes ion channel reconstruction to regulate colonic motility in rats with dinitrobenzene sulfonic acid-induced colitis. Ann Transl Med. 2022;10:681.","journal-title":"Ann Transl Med"},{"key":"3753_CR29","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1007\/s10620-012-2051-5","volume":"57","author":"SA Mard","year":"2012","unstructured":"Mard SA, Neisi N, Solgi G, Hassanpour M, Darbor M, Maleki M. Gastroprotective effect of NaHS against mucosal lesions induced by ischemia-reperfusion injury in rat. Dig Dis Sci. 2012;57:1496\u2013503.","journal-title":"Dig Dis Sci"},{"key":"3753_CR30","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.intimp.2016.07.020","volume":"39","author":"H Zhao","year":"2016","unstructured":"Zhao H, Yan R, Zhou X, Ji F, Zhang B. Hydrogen sulfide improves colonic barrier integrity in DSS-induced inflammation in Caco-2 cells and mice. Int Immunopharmacol. 2016;39:121\u20137.","journal-title":"Int Immunopharmacol"},{"key":"3753_CR31","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/mnfr.201400347","volume":"59","author":"I Fasolino","year":"2015","unstructured":"Fasolino I, Izzo AA, Clavel T, Romano B, Haller D, Borrelli F. Orally administered allyl sulfides from garlic ameliorate murine colitis. Mol Nutr Food Res. 2015;59:434\u201342.","journal-title":"Mol Nutr Food Res"},{"key":"3753_CR32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/0960327114537095","volume":"34","author":"IC Lee","year":"2015","unstructured":"Lee IC, Baek HS, Kim SH, Moon C, Park SH, Kim SH, et al. Effect of diallyl disulfide on acute gastric mucosal damage induced by alcohol in rats. Hum Exp Toxicol. 2015;34:227\u201339.","journal-title":"Hum Exp Toxicol"},{"key":"3753_CR33","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/bja\/aeg054","volume":"90","author":"AB Chiarella","year":"2003","unstructured":"Chiarella AB, Jolly DT, Huston CM, Clanachan AS. Comparison of four strategies to reduce the pain associated with intravenous administration of rocuronium. Br J Anaesth. 2003;90:377\u20139.","journal-title":"Br J Anaesth"},{"key":"3753_CR34","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.2147\/PPA.S106629","volume":"10","author":"D Eek","year":"2016","unstructured":"Eek D, Krohe M, Mazar I, Horsfield A, Pompilus F, Friebe R, et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016;10:1609\u201321.","journal-title":"Patient Prefer Adherence"},{"key":"3753_CR35","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2344\/0003-3006(2005)52[122:ASP]2.0.CO;2","volume":"52","author":"E Kaufman","year":"2005","unstructured":"Kaufman E, Epstein JB, Naveh E, Gorsky M, Gross A, Cohen G. A survey of pain, pressure, and discomfort induced by commonly used oral local anesthesia injections. Anesth Prog. 2005;52:122\u20137.","journal-title":"Anesth Prog"},{"key":"3753_CR36","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1089\/dia.2012.0038","volume":"14","author":"R Aronson","year":"2012","unstructured":"Aronson R. The role of comfort and discomfort in insulin therapy. Diabetes Technol Ther. 2012;14:741\u20137.","journal-title":"Diabetes Technol Ther"},{"key":"3753_CR37","first-page":"923","volume":"9","author":"JF Jin","year":"2015","unstructured":"Jin JF, Zhu LL, Chen M, Xu HM, Wang HF, Feng XQ, et al. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Prefer Adherence. 2015;9:923\u201342.","journal-title":"Patient Prefer Adherence"},{"key":"3753_CR38","doi-asserted-by":"publisher","first-page":"11788","DOI":"10.1039\/C4CC00968A","volume":"50","author":"Y Zhao","year":"2014","unstructured":"Zhao Y, Biggs TD, Xian M. Hydrogen sulfide (H2S) releasing agents: chemistry and biological applications. Chem Commun (Camb). 2014;50:11788\u2013805.","journal-title":"Chem Commun (Camb)"},{"key":"3753_CR39","first-page":"198","volume":"19","author":"F Rong","year":"2023","unstructured":"Rong F, Wang T, Zhou Q, Peng H, Yang J, Fan Q, et al. Intelligent polymeric hydrogen sulfide delivery systems for therapeutic applications. Bioact Mater. 2023;19:198\u2013216.","journal-title":"Bioact Mater"},{"key":"3753_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.actbio.2019.12.032","volume":"104","author":"X Zhao","year":"2020","unstructured":"Zhao X, Liu L, An T, Xian M, Luckanagul JA, Su Z, et al. A hydrogen sulfide-releasing alginate dressing for effective wound healing. Acta Biomater. 2020;104:85\u201394.","journal-title":"Acta Biomater"},{"key":"3753_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/med.21433","volume":"38","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Yu B, De La Cruz LK, Roy Choudhury M, Anifowose A, Wang B. Toward hydrogen sulfide based therapeutics: critical drug delivery and developability issues. Med Res Rev. 2018;38:57\u2013100.","journal-title":"Med Res Rev"},{"key":"3753_CR42","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.addr.2013.10.001","volume":"71","author":"C Lautenschlager","year":"2014","unstructured":"Lautenschlager C, Schmidt C, Fischer D, Stallmach A. Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Deliv Rev. 2014;71:58\u201376.","journal-title":"Adv Drug Deliv Rev"},{"key":"3753_CR43","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.nano.2015.02.018","volume":"11","author":"S Hua","year":"2015","unstructured":"Hua S, Marks E, Schneider JJ, Keely S. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine. 2015;11:1117\u201332.","journal-title":"Nanomedicine"},{"key":"3753_CR44","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.2217\/nnm.16.9","volume":"11","author":"TX Nguyen","year":"2016","unstructured":"Nguyen TX, Huang L, Gauthier M, Yang G, Wang Q. Recent advances in liposome surface modification for oral drug delivery. Nanomedicine (Lond). 2016;11:1169\u201385.","journal-title":"Nanomedicine (Lond)"},{"key":"3753_CR45","volume":"19","author":"B Zheng","year":"2024","unstructured":"Zheng B, Wang L, Yi Y, Yin J, Liang A. Design strategies, advances and future perspectives of colon-targeted delivery systems for the treatment of inflammatory bowel disease. Asian J Pharm Sci. 2024;19:100943.","journal-title":"Asian J Pharm Sci"},{"key":"3753_CR46","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jconrel.2024.04.047","volume":"370","author":"R Han","year":"2024","unstructured":"Han R, He H, Lu Y, Lu H, Shen S, Wu W. Oral targeted drug delivery to post-gastrointestinal sites. J Control Release. 2024;370:256\u201376.","journal-title":"J Control Release"},{"key":"3753_CR47","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1021\/acs.molpharmaceut.2c00222","volume":"19","author":"OA Abed","year":"2022","unstructured":"Abed OA, Attlassy Y, Xu J, Han K, Moon JJ. Emerging nanotechnologies and microbiome engineering for the treatment of inflammatory bowel disease. Mol Pharm. 2022;19:4393\u2013410.","journal-title":"Mol Pharm"},{"key":"3753_CR48","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41575-021-00539-w","volume":"19","author":"JN Chu","year":"2022","unstructured":"Chu JN, Traverso G. Foundations of gastrointestinal-based drug delivery and future developments. Nat Rev Gastroenterol Hepatol. 2022;19:219\u201338.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3753_CR49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1039\/D3TB02302H","volume":"12","author":"S Hu","year":"2023","unstructured":"Hu S, Zhao R, Xu Y, Gu Z, Zhu B, Hu J. Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: latest advances. J Mater Chem B. 2023;12:13\u201338.","journal-title":"J Mater Chem B"},{"key":"3753_CR50","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jconrel.2021.04.026","volume":"334","author":"AM Dos Santos","year":"2021","unstructured":"Dos Santos AM, Carvalho SG, Meneguin AB, Sabio RM, Gremiao MPD, Chorilli M. Oral delivery of micro\/nanoparticulate systems based on natural polysaccharides for intestinal diseases therapy: challenges, advances and future perspectives. J Control Release. 2021;334:353\u201366.","journal-title":"J Control Release"},{"key":"3753_CR51","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","volume":"64","author":"LM Ensign","year":"2012","unstructured":"Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev. 2012;64:557\u201370.","journal-title":"Adv Drug Deliv Rev"},{"key":"3753_CR52","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jconrel.2013.04.020","volume":"170","author":"K Thanki","year":"2013","unstructured":"Thanki K, Gangwal RP, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: challenges and opportunities. J Control Release. 2013;170:15\u201340.","journal-title":"J Control Release"},{"key":"3753_CR53","doi-asserted-by":"crossref","unstructured":"Nikam A, Sahoo PR, Musale S, Pagar RR, Paiva-Santos AC, Giram PS. A Systematic overview of Eudragit((R)) based copolymer for smart healthcare. Pharmaceutics 2023;15.","DOI":"10.3390\/pharmaceutics15020587"},{"key":"3753_CR54","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1021\/acsnano.2c08898","volume":"17","author":"C Oh","year":"2023","unstructured":"Oh C, Lee W, Park J, Choi J, Lee S, Li S, et al. Development of spleen targeting H(2)S donor loaded liposome for the effective systemic immunomodulation and treatment of inflammatory bowel disease. ACS Nano. 2023;17:4327\u201345.","journal-title":"ACS Nano"},{"key":"3753_CR55","first-page":"4557","volume":"7","author":"U Erben","year":"2014","unstructured":"Erben U, Loddenkemper C, Doerfel K, Spieckermann S, Haller D, Heimesaat MM, et al. A guide to histomorphological evaluation of intestinal inflammation in mouse models. Int J Clin Exp Pathol. 2014;7:4557\u201376.","journal-title":"Int J Clin Exp Pathol"},{"key":"3753_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10020057","volume":"10","author":"M Danaei","year":"2018","unstructured":"Danaei M, Dehghankhold M, Ataei S, HasanzadehDavarani F, Javanmard R, Dokhani A, et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018;10:57.","journal-title":"Pharmaceutics"},{"key":"3753_CR57","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2217\/nnm-2017-0381","volume":"13","author":"T Zhou","year":"2018","unstructured":"Zhou T, Lin Z, Puligujja P, Palandri D, Hilaire J, Arainga M, et al. Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals. Nanomedicine (Lond). 2018;13:871\u201385.","journal-title":"Nanomedicine (Lond)"},{"key":"3753_CR58","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3390\/coatings10020114","volume":"10","author":"V De Leo","year":"2020","unstructured":"De Leo V, Di Gioia S, Milano F, Fini P, Comparelli R, Mancini E, et al. Eudragit S100 entrapped liposome for curcumin delivery: anti-oxidative effect in Caco-2 cells. Coatings. 2020;10:114.","journal-title":"Coatings"},{"key":"3753_CR59","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S0168-3659(98)00151-5","volume":"58","author":"MZ Khan","year":"1999","unstructured":"Khan MZ, Prebeg Z, Kurjakovic N. A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers. I. Manipulation of drug release using Eudragit L100\u201355 and Eudragit S100 combinations. J Control Release. 1999;58:215\u201322.","journal-title":"J Control Release"},{"key":"3753_CR60","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3329\/icpj.v2i3.13577","volume":"2","author":"S Badhana","year":"2013","unstructured":"Badhana S, Garud N, Garud A. Colon specific drug delivery of mesalamine using eudragit S100-coated chitosan microspheres for the treatment of ulcerative colitis. Int Curr Pharm J. 2013;2:42\u20138.","journal-title":"Int Curr Pharm J"},{"key":"3753_CR61","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3109\/03639049709148695","volume":"23","author":"PJ Watts","year":"1997","unstructured":"Watts PJ, Lllum L. Colonic drug delivery. Drug Dev Ind Pharm. 1997;23:893\u2013913.","journal-title":"Drug Dev Ind Pharm"},{"key":"3753_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/nano14221800","author":"RJ Mow","year":"2024","unstructured":"Mow RJ, Kuczma MP, Shi X, Mani S, Merlin D, Yang C. Harnessing a safe novel lipid nanoparticle: targeted oral delivery to colonic epithelial and macrophage cells in a colitis mouse model. Nanomaterials. 2024. https:\/\/doi.org\/10.3390\/nano14221800.","journal-title":"Nanomaterials"},{"key":"3753_CR63","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13020-021-00449-8","volume":"16","author":"C Zhang","year":"2021","unstructured":"Zhang C, Chen Z, He Y, Xian J, Luo R, Zheng C, et al. Oral colon-targeting core-shell microparticles loading curcumin for enhanced ulcerative colitis alleviating efficacy. Chin Med. 2021;16:92.","journal-title":"Chin Med"},{"key":"3753_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2022.981055","volume":"10","author":"M Xiao","year":"2022","unstructured":"Xiao M, Wu S, Cheng Y, Ma J, Luo X, Chang L, et al. Colon-specific delivery of isoliquiritigenin by oral edible zein\/caseate nanocomplex for ulcerative colitis treatment. Front Chem. 2022;10:981055.","journal-title":"Front Chem"},{"key":"3753_CR65","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1208\/s12249-015-0350-9","volume":"16","author":"S Amidon","year":"2015","unstructured":"Amidon S, Brown JE, Dave VS. Colon-targeted oral drug delivery systems: design trends and approaches. AAPS PharmSciTech. 2015;16:731\u201341.","journal-title":"AAPS PharmSciTech"},{"key":"3753_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00524","volume":"11","author":"S Hua","year":"2020","unstructured":"Hua S. Advances in oral drug delivery for regional targeting in the gastrointestinal tract - influence of physiological, pathophysiological and pharmaceutical factors. Front Pharmacol. 2020;11:524.","journal-title":"Front Pharmacol"},{"key":"3753_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/nano14070557","author":"N Wang","year":"2024","unstructured":"Wang N, Chen L, Huang W, Gao Z, Jin M. Current advances of nanomaterial-based oral drug delivery for colorectal cancer treatment. Nanomaterials. 2024. https:\/\/doi.org\/10.3390\/nano14070557.","journal-title":"Nanomaterials"},{"key":"3753_CR68","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1053\/j.gastro.2014.04.041","volume":"147","author":"G Farrugia","year":"2014","unstructured":"Farrugia G, Szurszewski JH. Carbon monoxide, hydrogen sulfide, and nitric oxide as signaling molecules in the gastrointestinal tract. Gastroenterology. 2014;147:303\u201313.","journal-title":"Gastroenterology"},{"key":"3753_CR69","doi-asserted-by":"publisher","first-page":"15111","DOI":"10.1021\/ja508063s","volume":"136","author":"S Riahi","year":"2014","unstructured":"Riahi S, Rowley CN. Why can hydrogen sulfide permeate cell membranes? J Am Chem Soc. 2014;136:15111\u20133.","journal-title":"J Am Chem Soc"},{"key":"3753_CR70","doi-asserted-by":"publisher","first-page":"16633","DOI":"10.1073\/pnas.0902952106","volume":"106","author":"JC Mathai","year":"2009","unstructured":"Mathai JC, Missner A, Kugler P, Saparov SM, Zeidel ML, Lee JK, et al. No facilitator required for membrane transport of hydrogen sulfide. Proc Natl Acad Sci U S A. 2009;106:16633\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3753_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/gut.39.1.1","volume":"39","author":"MC Pitcher","year":"1996","unstructured":"Pitcher MC, Cummings JH. Hydrogen sulphide: a bacterial toxin in ulcerative colitis? Gut. 1996;39:1\u20134.","journal-title":"Gut"},{"key":"3753_CR72","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3390\/microorganisms3040866","volume":"3","author":"SB Singh","year":"2015","unstructured":"Singh SB, Lin HC. Hydrogen sulfide in physiology and diseases of the digestive tract. Microorganisms. 2015;3:866\u201389.","journal-title":"Microorganisms"},{"key":"3753_CR73","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41569-022-00741-6","volume":"20","author":"GK Kolluru","year":"2023","unstructured":"Kolluru GK, Shackelford RE, Shen X, Dominic P, Kevil CG. Sulfide regulation of cardiovascular function in health and disease. Nat Rev Cardiol. 2023;20:109\u201325.","journal-title":"Nat Rev Cardiol"},{"key":"3753_CR74","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/dna.2019.5067","volume":"39","author":"N Yang","year":"2020","unstructured":"Yang N, Liu Y, Li T, Tuo Q. Role of hydrogen sulfide in chronic diseases. DNA Cell Biol. 2020;39:187\u201396.","journal-title":"DNA Cell Biol"},{"key":"3753_CR75","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1089\/ars.2021.0004","volume":"36","author":"AG Buret","year":"2022","unstructured":"Buret AG, Allain T, Motta JP, Wallace JL. Effects of hydrogen sulfide on the microbiome: from toxicity to therapy. Antioxid Redox Signal. 2022;36:211\u20139.","journal-title":"Antioxid Redox Signal"},{"key":"3753_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12081570","author":"N Stummer","year":"2023","unstructured":"Stummer N, Feichtinger RG, Weghuber D, Kofler B, Schneider AM. Role of hydrogen sulfide in inflammatory bowel disease. Antioxidants. 2023. https:\/\/doi.org\/10.3390\/antiox12081570.","journal-title":"Antioxidants"},{"key":"3753_CR77","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jare.2022.03.010","volume":"44","author":"S Guo","year":"2023","unstructured":"Guo S, Huang Z, Zhu J, Yue T, Wang X, Pan Y, et al. CBS-H(2)S axis preserves the intestinal barrier function by inhibiting COX-2 through sulfhydrating human antigen R in colitis. J Adv Res. 2023;44:201\u201312.","journal-title":"J Adv Res"},{"key":"3753_CR78","doi-asserted-by":"publisher","first-page":"10038","DOI":"10.1073\/pnas.1507645112","volume":"112","author":"N Ijssennagger","year":"2015","unstructured":"Ijssennagger N, Belzer C, Hooiveld GJ, Dekker J, van Mil SW, Muller M, et al. Gut microbiota facilitates dietary heme-induced epithelial hyperproliferation by opening the mucus barrier in colon. Proc Natl Acad Sci U S A. 2015;112:10038\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3753_CR79","doi-asserted-by":"publisher","first-page":"13559","DOI":"10.1073\/pnas.1413390111","volume":"111","author":"KL Flannigan","year":"2014","unstructured":"Flannigan KL, Agbor TA, Blackler RW, Kim JJ, Khan WI, Verdu EF, et al. Impaired hydrogen sulfide synthesis and IL-10 signaling underlie hyperhomocysteinemia-associated exacerbation of colitis. Proc Natl Acad Sci U S A. 2014;111:13559\u201364.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3753_CR80","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1074\/jbc.M117.806869","volume":"293","author":"M Castelblanco","year":"2018","unstructured":"Castelblanco M, Lugrin J, Ehirchiou D, Nasi S, Ishii I, So A, et al. Hydrogen sulfide inhibits NLRP3 inflammasome activation and reduces cytokine production both in vitro and in a mouse model of inflammation. J Biol Chem. 2018;293:2546\u201357.","journal-title":"J Biol Chem"},{"key":"3753_CR81","doi-asserted-by":"publisher","first-page":"G143","DOI":"10.1152\/ajpgi.00249.2017","volume":"314","author":"JL Wallace","year":"2018","unstructured":"Wallace JL, Motta JP, Buret AG. Hydrogen sulfide: an agent of stability at the microbiome-mucosa interface. Am J Physiol Gastrointest Liver Physiol. 2018;314:G143-9.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"3753_CR82","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00011-015-0862-5","volume":"64","author":"SW Chen","year":"2015","unstructured":"Chen SW, Zhu J, Zuo S, Zhang JL, Chen ZY, Chen GW, et al. Protective effect of hydrogen sulfide on TNF-alpha and IFN-gamma-induced injury of intestinal epithelial barrier function in Caco-2 monolayers. Inflamm Res. 2015;64:789\u201397.","journal-title":"Inflamm Res"},{"key":"3753_CR83","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/ecco-jcc\/jjz027","volume":"13","author":"S Chen","year":"2019","unstructured":"Chen S, Zuo S, Zhu J, Yue T, Bu D, Wang X, et al. Decreased expression of cystathionine beta-synthase exacerbates intestinal barrier injury in ulcerative colitis. J Crohns Colitis. 2019;13:1067\u201380.","journal-title":"J Crohns Colitis"},{"key":"3753_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14132-y","volume":"11","author":"V Saini","year":"2020","unstructured":"Saini V, Chinta KC, Reddy VP, Glasgow JN, Stein A, Lamprecht DA, et al. Hydrogen sulfide stimulates Mycobacterium tuberculosis respiration, growth and pathogenesis. Nat Commun. 2020;11:557.","journal-title":"Nat Commun"},{"key":"3753_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-024-01873-2","volume":"12","author":"W Luo","year":"2024","unstructured":"Luo W, Zhao M, Dwidar M, Gao Y, Xiang L, Wu X, et al. Microbial assimilatory sulfate reduction-mediated H(2)S: an overlooked role in Crohn\u2019s disease development. Microbiome. 2024;12:152.","journal-title":"Microbiome"},{"key":"3753_CR86","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jare.2020.03.007","volume":"27","author":"I Kushkevych","year":"2021","unstructured":"Kushkevych I, Dordevic D, Vitezova M. Possible synergy effect of hydrogen sulfide and acetate produced by sulfate-reducing bacteria on inflammatory bowel disease development. J Adv Res. 2021;27:71\u20138.","journal-title":"J Adv Res"},{"key":"3753_CR87","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1152\/physrev.00028.2021","volume":"103","author":"G Cirino","year":"2023","unstructured":"Cirino G, Szabo C, Papapetropoulos A. Physiological roles of hydrogen sulfide in mammalian cells, tissues, and organs. Physiol Rev. 2023;103:31\u2013276.","journal-title":"Physiol Rev"},{"key":"3753_CR88","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/cbic.202000661","volume":"22","author":"AP Landry","year":"2021","unstructured":"Landry AP, Ballou DP, Banerjee R. Hydrogen sulfide oxidation by sulfide quinone oxidoreductase. Chembiochem. 2021;22:949\u201360.","journal-title":"Chembiochem"},{"key":"3753_CR89","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3389\/fphys.2017.00525","volume":"8","author":"CM Quinzii","year":"2017","unstructured":"Quinzii CM, Luna-Sanchez M, Ziosi M, Hidalgo-Gutierrez A, Kleiner G, Lopez LC. The role of sulfide oxidation impairment in the pathogenesis of primary CoQ deficiency. Front Physiol. 2017;8:525.","journal-title":"Front Physiol"},{"key":"3753_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.705583","volume":"12","author":"DJ Braccia","year":"2021","unstructured":"Braccia DJ, Jiang X, Pop M, Hall AB. The capacity to produce hydrogen sulfide (H2S) via cysteine degradation is ubiquitous in the human gut microbiome. Front Microbiol. 2021;12:705583.","journal-title":"Front Microbiol"},{"key":"3753_CR91","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.molmed.2016.01.002","volume":"22","author":"N Ijssennagger","year":"2016","unstructured":"Ijssennagger N, van der Meer R, van Mil SWC. Sulfide as a mucus barrier-breaker in inflammatory bowel disease? Trends Mol Med. 2016;22:190\u20139.","journal-title":"Trends Mol Med"},{"key":"3753_CR92","doi-asserted-by":"publisher","first-page":"G125","DOI":"10.1152\/ajpgi.00261.2020","volume":"320","author":"F Blachier","year":"2021","unstructured":"Blachier F, Andriamihaja M, Larraufie P, Ahn E, Lan A, Kim E. Production of hydrogen sulfide by the intestinal microbiota and epithelial cells and consequences for the colonic and rectal mucosa. Am J Physiol-Gastrointest Liver Physiol. 2021;320:G125-35.","journal-title":"Am J Physiol-Gastrointest Liver Physiol"},{"key":"3753_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11112235","author":"N Stummer","year":"2022","unstructured":"Stummer N, Weghuber D, Feichtinger RG, Huber S, Mayr JA, Kofler B, et al. Hydrogen sulfide metabolizing enzymes in the intestinal mucosa in pediatric and adult inflammatory bowel disease. Antioxidants. 2022. https:\/\/doi.org\/10.3390\/antiox11112235.","journal-title":"Antioxidants"},{"key":"3753_CR94","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/bjs.6454","volume":"96","author":"FE Rowan","year":"2009","unstructured":"Rowan FE, Docherty NG, Coffey JC, O\u2019Connell PR. Sulphate-reducing bacteria and hydrogen sulphide in the aetiology of ulcerative colitis. Br J Surg. 2009;96:151\u20138.","journal-title":"Br J Surg"},{"key":"3753_CR95","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jare.2020.03.003","volume":"27","author":"D Dordevic","year":"2021","unstructured":"Dordevic D, Jancikova S, Vitezova M, Kushkevych I. Hydrogen sulfide toxicity in the gut environment: meta-analysis of sulfate-reducing and lactic acid bacteria in inflammatory processes. J Adv Res. 2021;27:55\u201369.","journal-title":"J Adv Res"},{"key":"3753_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2012.00448","volume":"3","author":"F Carbonero","year":"2012","unstructured":"Carbonero F, Benefiel AC, Alizadeh-Ghamsari AH, Gaskins HR. Microbial pathways in colonic sulfur metabolism and links with health and disease. Front Physiol. 2012;3:448.","journal-title":"Front Physiol"},{"key":"3753_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-023-00443-y","volume":"9","author":"A Pena-Cearra","year":"2023","unstructured":"Pena-Cearra A, Song D, Castelo J, Palacios A, Lavin JL, Azkargorta M, et al. Mitochondrial dysfunction promotes microbial composition that negatively impacts on ulcerative colitis development and progression. NPJ Biofilms Microbiomes. 2023;9:74.","journal-title":"NPJ Biofilms Microbiomes"},{"key":"3753_CR98","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/878052","volume":"2012","author":"W Guo","year":"2012","unstructured":"Guo W, Kan JT, Cheng ZY, Chen JF, Shen YQ, Xu J, et al. Hydrogen sulfide as an endogenous modulator in mitochondria and mitochondria dysfunction. Oxid Med Cell Longev. 2012;2012:878052.","journal-title":"Oxid Med Cell Longev"},{"key":"3753_CR99","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1572-0241.1998.083_c.x","volume":"93","author":"J Levine","year":"1998","unstructured":"Levine J, Ellis CJ, Furne JK, Springfield J, Levitt MD. Fecal hydrogen sulfide production in ulcerative colitis. Am J Gastroenterol. 1998;93:83\u20137.","journal-title":"Am J Gastroenterol"},{"key":"3753_CR100","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1053\/j.gastro.2007.11.059","volume":"134","author":"RB Sartor","year":"2008","unstructured":"Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577\u201394.","journal-title":"Gastroenterology"},{"key":"3753_CR101","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1136\/gut.46.1.64","volume":"46","author":"MC Pitcher","year":"2000","unstructured":"Pitcher MC, Beatty ER, Cummings JH. The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut. 2000;46:64\u201372.","journal-title":"Gut"},{"key":"3753_CR102","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1007\/DCR.0b013e3181f1e620","volume":"53","author":"F Rowan","year":"2010","unstructured":"Rowan F, Docherty NG, Murphy M, Murphy B, Calvin Coffey J, O\u2019Connell PR. Desulfovibrio bacterial species are increased in ulcerative colitis. Dis Colon Rectum. 2010;53:1530\u20136.","journal-title":"Dis Colon Rectum"},{"key":"3753_CR103","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40168-023-01722-8","volume":"12","author":"R Xie","year":"2024","unstructured":"Xie R, Gu Y, Li M, Li L, Yang Y, Sun Y, et al. Desulfovibrio vulgaris interacts with novel gut epithelial immune receptor LRRC19 and exacerbates colitis. Microbiome. 2024;12:4.","journal-title":"Microbiome"},{"key":"3753_CR104","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1002\/ibd.22949","volume":"18","author":"V De Preter","year":"2012","unstructured":"De Preter V, Arijs I, Windey K, Vanhove W, Vermeire S, Schuit F, et al. Decreased mucosal sulfide detoxification is related to an impaired butyrate oxidation in ulcerative colitis. Inflamm Bowel Dis. 2012;18:2371\u201380.","journal-title":"Inflamm Bowel Dis"},{"key":"3753_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020220","author":"C Szabo","year":"2021","unstructured":"Szabo C. Hydrogen sulfide, an endogenous stimulator of mitochondrial function in cancer cells. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10020220.","journal-title":"Cells"},{"key":"3753_CR106","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3390\/molecules22020295","volume":"22","author":"M Magierowski","year":"2017","unstructured":"Magierowski M, Magierowska K, Hubalewska-Mazgaj M, Sliwowski Z, Pajdo R, Ginter G, et al. Exogenous and endogenous hydrogen sulfide protects gastric mucosa against the formation and time-dependent development of ischemia\/reperfusion-induced acute lesions progressing into deeper ulcerations. Molecules. 2017;22:295.","journal-title":"Molecules"},{"key":"3753_CR107","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1093\/ibd\/izy054","volume":"24","author":"M Madanchi","year":"2018","unstructured":"Madanchi M, Fagagnini S, Fournier N, Biedermann L, Zeitz J, Battegay E, et al. The relevance of vitamin and iron deficiency in patients with inflammatory bowel diseases in patients of the Swiss IBD cohort. Inflamm Bowel Dis. 2018;24:1768\u201379.","journal-title":"Inflamm Bowel Dis"},{"key":"3753_CR108","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/0148607107031004311","volume":"31","author":"K Vagianos","year":"2007","unstructured":"Vagianos K, Bector S, McConnell J, Bernstein CN. Nutrition assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr. 2007;31:311\u20139.","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"3753_CR109","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1572-0241.2003.07160.x","volume":"98","author":"S Saibeni","year":"2003","unstructured":"Saibeni S, Cattaneo M, Vecchi M, Zighetti ML, Lecchi A, Lombardi R, et al. Low vitamin B(6) plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. Am J Gastroenterol. 2003;98:112\u20137.","journal-title":"Am J Gastroenterol"},{"key":"3753_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102417","volume":"55","author":"KK Thanki","year":"2022","unstructured":"Thanki KK, Johnson P, Higgins EJ, Maskey M, Phillips C, Dash S, et al. Deletion of cystathionine-gamma-lyase in bone marrow-derived cells promotes colitis-associated carcinogenesis. Redox Biol. 2022;55:102417.","journal-title":"Redox Biol"},{"key":"3753_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.966881","volume":"13","author":"S Wang","year":"2022","unstructured":"Wang S, Ding Y, Jiang W. CSE\/H(2)S ameliorates colitis in mice via protection of enteric glial cells and inhibition of the RhoA\/ROCK pathway. Front Immunol. 2022;13:966881.","journal-title":"Front Immunol"},{"key":"3753_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102469","volume":"56","author":"J Zhang","year":"2022","unstructured":"Zhang J, Cen L, Zhang X, Tang C, Chen Y, Zhang Y, et al. MPST deficiency promotes intestinal epithelial cell apoptosis and aggravates inflammatory bowel disease via AKT. Redox Biol. 2022;56:102469.","journal-title":"Redox Biol"},{"key":"3753_CR113","doi-asserted-by":"publisher","first-page":"G281","DOI":"10.1152\/ajpgi.00423.2011","volume":"303","author":"S Givvimani","year":"2012","unstructured":"Givvimani S, Munjal C, Narayanan N, Aqil F, Tyagi G, Metreveli N, et al. Hyperhomocysteinemia decreases intestinal motility leading to constipation. Am J Physiol Gastrointest Liver Physiol. 2012;303:G281-290.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"3753_CR114","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/bph.12961","volume":"172","author":"RW Blackler","year":"2015","unstructured":"Blackler RW, Motta JP, Manko A, Workentine M, Bercik P, Surette MG, et al. Hydrogen sulphide protects against NSAID-enteropathy through modulation of bile and the microbiota. Br J Pharmacol. 2015;172:992\u20131004.","journal-title":"Br J Pharmacol"},{"key":"3753_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1476407","volume":"15","author":"S Pan","year":"2024","unstructured":"Pan S, Yan H, Zhu J, Ma Y, Wang P, Liu Y, et al. GYY4137, as a slow-releasing H(2)S donor, ameliorates sodium deoxycholate-induced chronic intestinal barrier injury and gut microbiota dysbiosis. Front Pharmacol. 2024;15:1476407.","journal-title":"Front Pharmacol"},{"key":"3753_CR116","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S0140-6736(81)90523-7","volume":"2","author":"M Campieri","year":"1981","unstructured":"Campieri M, Lanfranchi GA, Bazzocchi G, Brignola C, Sarti F, Franzin G, et al. Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet. 1981;2:270\u20131.","journal-title":"Lancet"},{"key":"3753_CR117","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1111\/apt.14688","volume":"47","author":"P Sehgal","year":"2018","unstructured":"Sehgal P, Colombel JF, Aboubakr A, Narula N. Systematic review: safety of mesalazine in ulcerative colitis. Aliment Pharmacol Ther. 2018;47:1597\u2013609.","journal-title":"Aliment Pharmacol Ther"},{"key":"3753_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103335","volume":"72","author":"S Aib","year":"2022","unstructured":"Aib S, Iqbal K, Khan N, Khalid S, Adnan M, Umair SM, et al. Ph-sensitive liposomes for colonic co-delivery of mesalazine and curcumin for the treatment of ulcerative colitis. J Drug Deliv Sci Technol. 2022;72:103335.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3753_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2020.111582","volume":"119","author":"A Ahmad","year":"2021","unstructured":"Ahmad A, Ansari MM, Mishra RK, Kumar A, Vyawahare A, Verma RK, et al. Enteric-coated gelatin nanoparticles mediated oral delivery of 5-aminosalicylic acid alleviates severity of DSS-induced ulcerative colitis. Mater Sci Eng C Mater Biol Appl. 2021;119:111582.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"3753_CR120","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-02097-6","volume":"21","author":"L Qiu","year":"2023","unstructured":"Qiu L, Shen R, Wei L, Xu S, Xia W, Hou Y, et al. Designing a microbial fermentation-functionalized alginate microsphere for targeted release of 5-ASA using nano dietary fiber carrier for inflammatory bowel disease treatment. J Nanobiotechnol. 2023;21:344.","journal-title":"J Nanobiotechnol"},{"key":"3753_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.102540","volume":"63","author":"M Wang","year":"2021","unstructured":"Wang M, Hao W, Zhang L, Zhu Y, Chen K, Ma S, et al. Lipid-polymer nano core-shell type hybrid system for colon specific drug delivery. J Drug Deliv Sci Technol. 2021;63:102540.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3753_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.125332","volume":"244","author":"S Mahami","year":"2023","unstructured":"Mahami S, Salehi M, Mehrabi M, Vahedi H, Hassani MS, Bitaraf FS, et al. pH-sensitive HPMCP-chitosan nanoparticles containing 5-aminosalicylic acid and berberine for oral colon delivery in a rat model of ulcerative colitis. Int J Biol Macromol. 2023;244:125332.","journal-title":"Int J Biol Macromol"},{"key":"3753_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103578","volume":"74","author":"N Wang","year":"2022","unstructured":"Wang N, Shao L, Lu W, Fang W, Zhang Q, Sun L, et al. 5-aminosalicylic acid pH sensitive core-shell nanoparticles targeting ulcerative colitis. J Drug Deliv Sci Technol. 2022;74:103578.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3753_CR124","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ijbiomac.2016.11.066","volume":"95","author":"R Kaur","year":"2017","unstructured":"Kaur R, Gulati M, Singh SK. Role of synbiotics in polysaccharide assisted colon targeted microspheres of mesalamine for the treatment of ulcerative colitis. Int J Biol Macromol. 2017;95:438\u201350.","journal-title":"Int J Biol Macromol"},{"key":"3753_CR125","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ijbiomac.2018.12.154","volume":"126","author":"S Mohanta","year":"2019","unstructured":"Mohanta S, Singh SK, Kumar B, Gulati M, Kumar R, Yadav AK, et al. Efficacy of co-administration of modified apple polysaccharide and probiotics in guar gum-Eudragit S100 based mesalamine mini tablets: a novel approach in treating ulcerative colitis. Int J Biol Macromol. 2019;126:427\u201335.","journal-title":"Int J Biol Macromol"},{"key":"3753_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.114021","volume":"179","author":"Y Lee","year":"2021","unstructured":"Lee Y, Kamada N, Moon JJ. Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome. Adv Drug Deliv Rev. 2021;179:114021.","journal-title":"Adv Drug Deliv Rev"},{"key":"3753_CR127","doi-asserted-by":"publisher","first-page":"8875","DOI":"10.2147\/IJN.S210315","volume":"14","author":"C Yang","year":"2019","unstructured":"Yang C, Merlin D. Nanoparticle-mediated drug delivery systems for the treatment of IBD: current perspectives. Int J Nanomedicine. 2019;14:8875\u201389.","journal-title":"Int J Nanomedicine"},{"key":"3753_CR128","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.3390\/pr13082477","volume":"13","author":"MA Haque","year":"2025","unstructured":"Haque MA, Shrestha A, Mattheolabakis G. Eudragit\u00ae s 100 coating of lipid nanoparticles for oral delivery of RNA. Processes. 2025;13:2477.","journal-title":"Processes"},{"key":"3753_CR129","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.123597","volume":"648","author":"H Alghurabi","year":"2023","unstructured":"Alghurabi H, Jassim Muhammad H, Tagami T, Ogawa K, Ozeki T. Optimization, cellular uptake, and in vivo evaluation of Eudragit S100-coated bile salt-containing liposomes for oral colonic delivery of 5-aminosalicylic acid. Int J Pharm. 2023;648:123597.","journal-title":"Int J Pharm"},{"key":"3753_CR130","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ejps.2010.12.007","volume":"42","author":"A Makhlof","year":"2011","unstructured":"Makhlof A, Tozuka Y, Takeuchi H. Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery. Eur J Pharm Sci. 2011;42:445\u201351.","journal-title":"Eur J Pharm Sci"},{"key":"3753_CR131","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2024.123063","volume":"350","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Zhang X, Lv L, Gao S, Li X, Wang R, et al. Versatile inulin\/trans-ferulic acid\/silk sericin nanoparticles-nourished probiotic complex with prolonged intestinal retention for synergistic therapy of inflammatory bowel disease. Carbohydr Polym. 2025;350:123063.","journal-title":"Carbohydr Polym"},{"key":"3753_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.134899","author":"X Liu","year":"2024","unstructured":"Liu X, Dong Y, Wang C, Guo Z. Application of chitosan as nano carrier in the treatment of inflammatory bowel disease. Int J Biol Macromol. 2024. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.134899.","journal-title":"Int J Biol Macromol"},{"key":"3753_CR133","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1038\/s41467-022-31171-0","volume":"13","author":"J Zhou","year":"2022","unstructured":"Zhou J, Li M, Chen Q, Li X, Chen L, Dong Z, et al. Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery. Nat Commun. 2022;13:3432.","journal-title":"Nat Commun"},{"key":"3753_CR134","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0378-5173(98)00172-0","volume":"171","author":"Y Krishnaiah","year":"1998","unstructured":"Krishnaiah Y, Satyanarayana S, Prasad YR, Rao SN. Evaluation of guar gum as a compression coat for drug targeting to colon. Int J Pharm. 1998;171:137\u201346.","journal-title":"Int J Pharm"},{"key":"3753_CR135","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3390\/pharmaceutics15020402","volume":"15","author":"M Jadav","year":"2023","unstructured":"Jadav M, Pooja D, Adams DJ, Kulhari H. Advances in xanthan gum-based systems for the delivery of therapeutic agents. Pharmaceutics. 2023;15:402.","journal-title":"Pharmaceutics"},{"key":"3753_CR136","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/gut.48.4.571","volume":"48","author":"SG Nugent","year":"2001","unstructured":"Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 2001;48:571\u20137.","journal-title":"Gut"},{"key":"3753_CR137","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/BF01297074","volume":"38","author":"J Fallingborg","year":"1993","unstructured":"Fallingborg J, Christensen LA, Jacobsen BA, Rasmussen SN. Very low intraluminal colonic pH in patients with active ulcerative colitis. Dig Dis Sci. 1993;38:1989\u201393.","journal-title":"Dig Dis Sci"},{"key":"3753_CR138","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/MOG.0000000000001064","volume":"41","author":"C Yeung","year":"2025","unstructured":"Yeung C, Mccoubrey LE, Basit AW. Advances in colon-targeted drug technologies. Curr Opin Gastroenterol. 2025;41:9\u201315.","journal-title":"Curr Opin Gastroenterol"},{"key":"3753_CR139","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i1.37","volume":"20","author":"G Bassotti","year":"2014","unstructured":"Bassotti G, Antonelli E, Villanacci V, Salemme M, Coppola M, Annese V. Gastrointestinal motility disorders in inflammatory bowel diseases. World J Gastroenterol. 2014;20:37.","journal-title":"World J Gastroenterol"},{"key":"3753_CR140","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1208\/s12249-016-0521-3","volume":"18","author":"M Fischer","year":"2017","unstructured":"Fischer M, Siva S, Wo JM, Fadda HM. Assessment of small intestinal transit times in ulcerative colitis and Crohn\u2019s disease patients with different disease activity using video capsule endoscopy. AAPS PharmSciTech. 2017;18:404\u20139.","journal-title":"AAPS PharmSciTech"},{"key":"3753_CR141","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/ibd\/izy123","volume":"24","author":"M Zhang","year":"2018","unstructured":"Zhang M, Merlin D. Nanoparticle-based oral drug delivery systems targeting the colon for treatment of ulcerative colitis. Inflamm Bowel Dis. 2018;24:1401\u201315.","journal-title":"Inflamm Bowel Dis"},{"key":"3753_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.133665","volume":"275","author":"S Zhang","year":"2024","unstructured":"Zhang S, Li C. A curcumin-loaded biopolymeric nanocomposite alleviates dextran sulfate sodium induced ulcerative colitis via suppression of inflammation and oxidative stress. Int J Biol Macromol. 2024;275:133665.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"3753_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-84322-2","volume":"15","author":"C Wu","year":"2025","unstructured":"Wu C, Bi C, Kim GS, Yang Z, Li S, Dai T, et al. Oral colon-targeted responsive chitosan\/pectin-based nanoparticles propels the application of tofacitinib in colitis therapy. Sci Rep. 2025;15(1):1569.","journal-title":"Sci Rep"},{"key":"3753_CR144","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3390\/molecules29061291","volume":"29","author":"W Zhang","year":"2024","unstructured":"Zhang W, Zhang X, Lv X, Qu A, Liang W, Wang L, et al. Oral delivery of astaxanthin via carboxymethyl chitosan-modified nanoparticles for ulcerative colitis treatment. Molecules. 2024;29:1291.","journal-title":"Molecules"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03753-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03753-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03753-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:04:03Z","timestamp":1762877043000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-025-03753-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":144,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3753"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03753-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6839836\/v1","asserted-by":"object"}]},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"712"}}